Rachel F Buckley1,2,3,4, Bernard Hanseeuw4,5,6, Aaron P Schultz3,5,7, Patrizia Vannini3,4,5, Sarah L Aghjayan8, Michael J Properzi3, Jonathan D Jackson3,4,8, Elizabeth C Mormino3,4, Dorene M Rentz3,4,8, Reisa A Sperling3,4,8, Keith A Johnson3,4,5,8,9, Rebecca E Amariglio3,4,8. 1. Florey Institutes of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia. 2. Melbourne School of Psychological Science, University of Melbourne, Australia. 3. Athinoula A. Martinos Center for Biomedical Imaging, Department of Neurology, Massachusetts General Hospital, Charlestown. 4. Department of Radiology, Harvard Medical School, Boston, Massachusetts. 5. Department of Radiology, Massachusetts General Hospital, Boston. 6. now affiliated with Department of Neurology, Cliniques Universitaires Saint-Luc, Institute of Neuroscience, Université Catholique de Louvain, Brussels, Belgium. 7. Department of Psychiatry, Massachusetts General Hospital, Boston. 8. Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts. 9. Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Boston.
Abstract
Importance: The ability to explore associations between reports of subjective cognitive decline (SCD) and biomarkers of early Alzheimer disease (AD) pathophysiologic processes (accumulation of neocortical β-amyloid [Aβ] and tau) provides an important opportunity to understand the basis of SCD and AD risk. Objective: To examine associations between SCD and global Aβ and tau burdens in regions of interest in clinically healthy older adults. Design, Setting, and Participants: This imaging substudy of the Harvard Aging Brain Study included 133 clinically healthy older participants (Clinical Dementia Rating Scale global scores of 0) participating in the Harvard Aging Brain Study who underwent cross-sectional flortaucipir F 18 (previously known as AV 1451, T807) positron emission tomography (FTP-PET) imaging for tau and Pittsburgh compound B carbon 11-labeled PET (PiB-PET) imaging for Aβ. The following 2 regions for tau burden were identified: the entorhinal cortex, which exhibits early signs of tauopathy, and the inferior temporal region, which is more closely associated with AD-related pathologic mechanisms. Data were collected from June 11, 2012, through April 7, 2016. Main Outcomes and Measures: Subjective cognitive decline was measured using a previously published method of z-transforming subscales from the Memory Functioning Questionnaire, the Everyday Cognition battery, and a 7-item questionnaire. The Aβ level was measured according to a summary distribution volume ratio of frontal, lateral temporal and parietal, and retrosplenial PiB-PET tracer uptake. The FTP-PET measures were computed as standardized uptake value ratios. Linear regression models focused on main and interactive effects of Aβ, entorhinal cortical, and inferior temporal tau on SCD, controlling for age, sex, educational attainment, and Geriatric Depression Scale score. Results: Of the 133 participants, 75 (56.3%) were women and 58 (43.6%) were men; mean (SD) age was 76 (6.9) years (range, 55-90 years). Thirty-nine participants (29.3%) exhibited a high Aβ burden. Greater SCD was associated with increasing entorhinal cortical tau burden (β = 0.35; 95% CI, 0.19-.52; P < .001) and Aβ burden (β = 0.24; 95% CI, 0.08-.40; P = .005), but not inferior temporal tau burden (β = 0.10; 95% CI, -0.08 to 0.28; P = .27). This association between entorhinal cortical tau burden and SCD was largely unchanged after accounting for Aβ burden (β = 0.36; 95% CI, 0.15-.58; P = .001), and no interaction influenced SCD (β = -0.36; 95% CI, -0.34 to 0.09; P = .25). An exploratory post hoc whole-brain analysis also indicated that SCD was predominantly associated with greater tau burden in the entorhinal cortex. Conclusions and Relevance: Subjective cognitive decline is indicative of accumulation of early tauopathy in the medial temporal lobe, specifically in the entorhinal cortex, and to a lesser extent, elevated global levels of Aβ. Our findings suggest multiple underlying pathways that motivate SCD that do not necessarily interact to influence SCD endorsement. As such, multiple biological factors must be considered when assessing SCD in clinically healthy older adults.
Importance: The ability to explore associations between reports of subjective cognitive decline (SCD) and biomarkers of early Alzheimer disease (AD) pathophysiologic processes (accumulation of neocortical β-amyloid [Aβ] and tau) provides an important opportunity to understand the basis of SCD and AD risk. Objective: To examine associations between SCD and global Aβ and tau burdens in regions of interest in clinically healthy older adults. Design, Setting, and Participants: This imaging substudy of the Harvard Aging Brain Study included 133 clinically healthy older participants (Clinical Dementia Rating Scale global scores of 0) participating in the Harvard Aging Brain Study who underwent cross-sectional flortaucipir F 18 (previously known as AV 1451, T807) positron emission tomography (FTP-PET) imaging for tau and Pittsburgh compound B carbon 11-labeled PET (PiB-PET) imaging for Aβ. The following 2 regions for tau burden were identified: the entorhinal cortex, which exhibits early signs of tauopathy, and the inferior temporal region, which is more closely associated with AD-related pathologic mechanisms. Data were collected from June 11, 2012, through April 7, 2016. Main Outcomes and Measures: Subjective cognitive decline was measured using a previously published method of z-transforming subscales from the Memory Functioning Questionnaire, the Everyday Cognition battery, and a 7-item questionnaire. The Aβ level was measured according to a summary distribution volume ratio of frontal, lateral temporal and parietal, and retrosplenial PiB-PET tracer uptake. The FTP-PET measures were computed as standardized uptake value ratios. Linear regression models focused on main and interactive effects of Aβ, entorhinal cortical, and inferior temporal tau on SCD, controlling for age, sex, educational attainment, and Geriatric Depression Scale score. Results: Of the 133 participants, 75 (56.3%) were women and 58 (43.6%) were men; mean (SD) age was 76 (6.9) years (range, 55-90 years). Thirty-nine participants (29.3%) exhibited a high Aβ burden. Greater SCD was associated with increasing entorhinal cortical tau burden (β = 0.35; 95% CI, 0.19-.52; P < .001) and Aβ burden (β = 0.24; 95% CI, 0.08-.40; P = .005), but not inferior temporal tau burden (β = 0.10; 95% CI, -0.08 to 0.28; P = .27). This association between entorhinal cortical tau burden and SCD was largely unchanged after accounting for Aβ burden (β = 0.36; 95% CI, 0.15-.58; P = .001), and no interaction influenced SCD (β = -0.36; 95% CI, -0.34 to 0.09; P = .25). An exploratory post hoc whole-brain analysis also indicated that SCD was predominantly associated with greater tau burden in the entorhinal cortex. Conclusions and Relevance: Subjective cognitive decline is indicative of accumulation of early tauopathy in the medial temporal lobe, specifically in the entorhinal cortex, and to a lesser extent, elevated global levels of Aβ. Our findings suggest multiple underlying pathways that motivate SCD that do not necessarily interact to influence SCD endorsement. As such, multiple biological factors must be considered when assessing SCD in clinically healthy older adults.
Authors: Sarah Tomaszewski Farias; Dan Mungas; Bruce R Reed; Deborah Cahn-Weiner; William Jagust; Kathleen Baynes; Charles Decarli Journal: Neuropsychology Date: 2008-07 Impact factor: 3.295
Authors: T Luck; M Luppa; H Matschinger; F Jessen; M C Angermeyer; S G Riedel-Heller Journal: Acta Psychiatr Scand Date: 2014-09-09 Impact factor: 6.392
Authors: Bernard J Hanseeuw; Rebecca A Betensky; Aaron P Schultz; Kathryn V Papp; Elizabeth C Mormino; Jorge Sepulcre; John S Bark; Danielle M Cosio; Molly LaPoint; Jasmeer P Chhatwal; Dorene M Rentz; Reisa A Sperling; Keith A Johnson Journal: Ann Neurol Date: 2017-04-06 Impact factor: 10.422
Authors: Peter T Nelson; Irina Alafuzoff; Eileen H Bigio; Constantin Bouras; Heiko Braak; Nigel J Cairns; Rudolph J Castellani; Barbara J Crain; Peter Davies; Kelly Del Tredici; Charles Duyckaerts; Matthew P Frosch; Vahram Haroutunian; Patrick R Hof; Christine M Hulette; Bradley T Hyman; Takeshi Iwatsubo; Kurt A Jellinger; Gregory A Jicha; Enikö Kövari; Walter A Kukull; James B Leverenz; Seth Love; Ian R Mackenzie; David M Mann; Eliezer Masliah; Ann C McKee; Thomas J Montine; John C Morris; Julie A Schneider; Joshua A Sonnen; Dietmar R Thal; John Q Trojanowski; Juan C Troncoso; Thomas Wisniewski; Randall L Woltjer; Thomas G Beach Journal: J Neuropathol Exp Neurol Date: 2012-05 Impact factor: 3.685
Authors: Steffen Wolfsgruber; Frank Jessen; Alexander Koppara; Luca Kleineidam; Klaus Schmidtke; Lutz Frölich; Alexander Kurz; Stefanie Schulz; Harald Hampel; Isabella Heuser; Oliver Peters; Friedel M Reischies; Holger Jahn; Christian Luckhaus; Michael Hüll; Hermann-Josef Gertz; Johannes Schröder; Johannes Pantel; Otto Rienhoff; Eckart Rüther; Fritz Henn; Jens Wiltfang; Wolfgang Maier; Johannes Kornhuber; Michael Wagner Journal: Neurology Date: 2015-02-25 Impact factor: 9.910
Authors: B C Dickerson; I Goncharova; M P Sullivan; C Forchetti; R S Wilson; D A Bennett; L A Beckett; L deToledo-Morrell Journal: Neurobiol Aging Date: 2001 Sep-Oct Impact factor: 4.673
Authors: Reisa A Sperling; Peter S Laviolette; Kelly O'Keefe; Jacqueline O'Brien; Dorene M Rentz; Maija Pihlajamaki; Gad Marshall; Bradley T Hyman; Dennis J Selkoe; Trey Hedden; Randy L Buckner; J Alex Becker; Keith A Johnson Journal: Neuron Date: 2009-07-30 Impact factor: 17.173
Authors: Keith A Johnson; Aaron Schultz; Rebecca A Betensky; J Alex Becker; Jorge Sepulcre; Dorene Rentz; Elizabeth Mormino; Jasmeer Chhatwal; Rebecca Amariglio; Kate Papp; Gad Marshall; Mark Albers; Samantha Mauro; Lesley Pepin; Jonathan Alverio; Kelly Judge; Marlie Philiossaint; Timothy Shoup; Daniel Yokell; Bradford Dickerson; Teresa Gomez-Isla; Bradley Hyman; Neil Vasdev; Reisa Sperling Journal: Ann Neurol Date: 2015-12-15 Impact factor: 10.422
Authors: David W Sanders; Sarah K Kaufman; Sarah L DeVos; Apurwa M Sharma; Hilda Mirbaha; Aimin Li; Scarlett J Barker; Alex C Foley; Julian R Thorpe; Louise C Serpell; Timothy M Miller; Lea T Grinberg; William W Seeley; Marc I Diamond Journal: Neuron Date: 2014-05-22 Impact factor: 17.173
Authors: J Alex Becker; Trey Hedden; Jeremy Carmasin; Jacqueline Maye; Dorene M Rentz; Deepti Putcha; Bruce Fischl; Douglas N Greve; Gad A Marshall; Stephen Salloway; Donald Marks; Randy L Buckner; Reisa A Sperling; Keith A Johnson Journal: Ann Neurol Date: 2011-03-17 Impact factor: 10.422
Authors: Victor L Villemagne; D Velakoulis; V Doré; S Bozinoski; C L Masters; C C Rowe; Mark Walterfang Journal: Eur J Nucl Med Mol Imaging Date: 2019-01-28 Impact factor: 9.236
Authors: Sepideh Shokouhi; Alexander C Conley; Suzanne L Baker; Kimberly Albert; Hakmook Kang; Harry E Gwirtsman; Paul A Newhouse Journal: Neurobiol Aging Date: 2019-05-23 Impact factor: 4.673
Authors: Jennifer R Gatchel; Francisco Lopera; Daniel J Norton; Ana Baena; Edmarie Guzman-Velez; Justin S Sanchez; Federico d'Oleire Uquillas; Aaron Schultz; Patrizia Vannini; Arabiye Artola; Rebecca E Amariglio; Dorene M Rentz; Pierre N Tariot; Eric M Reiman; Keith A Johnson; Reisa A Sperling; Gad A Marshall; Yakeel T Quiroz Journal: J Neurol Neurosurg Psychiatry Date: 2019-12-24 Impact factor: 10.154
Authors: Tzu-An Song; Fan Yang; Samadrita Roy Chowdhury; Kyungsang Kim; Keith A Johnson; Georges El Fakhri; Quanzheng Li; Joyita Dutta Journal: IEEE Trans Comput Imaging Date: 2019-04-25
Authors: Frank Jessen; Rebecca E Amariglio; Rachel F Buckley; Wiesje M van der Flier; Ying Han; José Luis Molinuevo; Laura Rabin; Dorene M Rentz; Octavio Rodriguez-Gomez; Andrew J Saykin; Sietske A M Sikkes; Colette M Smart; Steffen Wolfsgruber; Michael Wagner Journal: Lancet Neurol Date: 2020-01-17 Impact factor: 44.182
Authors: Joseph R Winer; Allison Morehouse; Laura Fenton; Theresa M Harrison; Lylian Ayangma; Mark Reed; Samika Kumar; Suzanne L Baker; William J Jagust; Matthew P Walker Journal: J Neurosci Date: 2021-07-21 Impact factor: 6.167